CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 186 enrolled
Drug / intervention
ASP0819 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03056690
NCT03056690Phase 2Completed
CompareCT.gov

A Phase 2a, Randomized, Double-Blind Placebo-controlled, Parallel-group Study to Assess the Analgesic Efficacy and Safety of ASP0819 in Patients With Fibromyalgia

Astellas Pharma Global Development, Inc.·interventional·Posted Feb 17, 2017·Updated Oct 29, 2024

In Brief

A Phase 2 clinical trial evaluating ASP0819 and Placebo for Fibromyalgia. Completed, enrolled 186 participants across 24 sites.

Detailed Summary

This study assessed analgesic efficacy of ASP0819 relative to placebo as well as the safety and tolerability. This study assessed treatment differences in physical function as well as the improvements in overall subject status (e.g., fibromyalgia symptoms and global functioning) of ASP0819 relative to placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFibromyalgia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 17, 2017
Enrollment StartMar 20, 2017
Primary CompletionFeb 27, 2018
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 9.4 years ago

Interventions

ASP0819drug

Oral capsule

Placebodrug

Oral capsule